Disease-specific changes in reelin protein and mRNA in neurodegenerative diseases
Visualitza/Obre
Autor/a
Lidón, Laia
Urrea, Laura
Llorens, Franc
Gil, Vanessa
Alvarez, Ignacio
Diez-Fairen, Monica
Aguilar, Miguel
Pastor, Pau
Zerr, Inga
Alcolea, Daniel
Lleó, Alberto
Gavín, Rosalina
Ferrer, Isidre
Del Rio, Jose Antonio
Data de publicació
2020-05-19ISSN
2073-4409
Resum
Reelin is an extracellular glycoprotein that modulates neuronal function and synaptic plasticity in the adult brain. Decreased levels of Reelin activity have been postulated as a key factor during neurodegeneration in Alzheimer´s disease (AD) and in aging. Thus, changes in levels of full-length Reelin and Reelin fragments have been revealed in cerebrospinal fluid (CSF) and in post-mortem brains samples of AD patients with respect to non-AD patients. However, conflicting studies have reported decreased or unchanged levels of full-length Reelin in AD patients compared to control (nND) cases in post-mortem brains and CSF samples. In addition, a compelling analysis of Reelin levels in neurodegenerative diseases other than AD is missing. In this study, we analyzed brain levels of RELN mRNA and Reelin protein in post-mortem frontal cortex samples from different sporadic AD stages, Parkinson's disease with dementia (PDD), and Creutzfeldt-Jakob disease (sCJD), obtained from five different Biobanks. In addition, we measured Reelin protein levels in CSF samples of patients with mild cognitive impairment (MCI), dementia, or sCJD diagnosis and a group of neurologically healthy cases. The results indicate an increase in RELN mRNA in the frontal cortex of advanced stages of AD and in sCJD(I) compared to controls. This was not observed in PDD and early AD stages. However, Reelin protein levels in frontal cortex samples were unchanged between nND and advanced AD stages and PDD. Nevertheless, they decreased in the CSF of patients with dementia in comparison to those not suffering with dementia and patients with MCI. With respect to sCJD, there was a tendency to increase in brain samples in comparison to nND and to decrease in the CSF with respect to nND. In conclusion, Reelin levels in CSF cannot be considered as a diagnostic biomarker for AD or PDD. However, we feel that the CSF Reelin changes observed between MCI, patients with dementia, and sCJD might be helpful in generating a biomarker signature in prodromal studies of unidentified dementia and sCJD.
Tipus de document
Article
Versió del document
Versió publicada
Llengua
Anglès
Matèries (CDU)
619 - Veterinària
Pàgines
18
Publicat per
MDPI
Publicat a
Cells
Citació
Lidón, Laia, Laura Urrea, Franc Llorens, Vanessa Gil, Ignacio Alvarez, Monica Diez-Fairen, and Miguel Aguilar et al. 2020. "Disease-Specific Changes In Reelin Protein And Mrna In Neurodegenerative Diseases". Cells 9 (5): 1252. MDPI AG. doi:10.3390/cells9051252.
Número de l'acord de la subvenció
MCIU-AEI-FEDER/Programa estatal de I+D+i orientada a los retos de la sociedad/RTI2018-099773-B-I00/ES/NUEVAS APROXIMACIONES PARA ENTENDER LAS FUNCIONES DE LA PRPC Y MIEMBROS SECRETABLES DE SEMAFORINAS DURANTE EL DESARROLLO DEL HIPOCAMPO Y EN NEUROTRANSMISION/
Programa
Sanitat Animal
Aquest element apareix en la col·lecció o col·leccions següent(s)
- ARTICLES CIENTÍFICS [2542]
Els següents fitxers sobre la llicència estan associats a aquest element:
Excepte que s'indiqui una altra cosa, la llicència de l'ítem es descriu com http://creativecommons.org/licenses/by/4.0/